Patent application number | Description | Published |
20080214788 | INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 09-04-2008 |
20080279816 | HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29 - Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity. | 11-13-2008 |
20090069274 | INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 03-12-2009 |
20090081168 | METHOD OF FORMING A PEPTIDE-RECEPTOR COMPLEX WITH ZSIG33 - The present invention relates to a method of forming a peptide-receptor complex with zsig33 polypeptides and their receptors as well as antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included. | 03-26-2009 |
20090149636 | CYTOKINE PROTEIN FAMILY - The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides. | 06-11-2009 |
20090156795 | ZSIG33-LIKE POLYNUCLEOTIDES - The present invention relates to polynucleotide related to the zsig33 peptide, including agonists, antagonists, and antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included. | 06-18-2009 |
20090270333 | Methods of using motilin homologs - The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules. | 10-29-2009 |
20090326204 | INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 12-31-2009 |
20100104531 | HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29 - Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity. | 04-29-2010 |
20100167391 | GROWTH FACTOR HOMOLOG ZVEGF3 - Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents. | 07-01-2010 |
20100222266 | A METHOD OF USING INTERFERON-LIKE PROTEIN ZCYTO21(IL-29) TO TREAT HEPATITIS B - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-a at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 09-02-2010 |
20100227813 | A METHOD OF USING INTERFERON-LIKE POTEIN ZCYTO20 (IL-28A) OR ZCYTO22(IL-28B) TO TREAT HEPATITIS B - The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides. | 09-09-2010 |
20100298230 | USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS - Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics. | 11-25-2010 |
20110054148 | ANTIBODIES TO INTERFERON-LIKE PROTEIN ZCYTO21(IL-29) - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 03-03-2011 |
20110151480 | METHODS OF PURIFYING ZSIG33 - The present invention relates to a method of forming a peptide-receptor complex with zsig33 polypeptides and their receptors as well as antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included. | 06-23-2011 |
20110151536 | THROMBIN ACTIVATOR COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Disclosed are compositions for activating thrombin precursors to thrombin. The compositions provided include polypeptide compositions wherein the pre-pro-sequence comprises a thrombin cleavage site. The compositions provided also include polynucleotides encoding said polypeptides and recombinant systems for expressing said polypeptides. This disclosure also relates to methods for producing said compositions, recovering said compositions, activating said compositions purifying said compositions and producing active thrombin molecules using the active form of said compositions. | 06-23-2011 |
20110172170 | INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 07-14-2011 |
20110177024 | USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS - Methods for treating patients with cancer and autoimmune disorders using IL- | 07-21-2011 |
20110182852 | IL28 AND IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME - IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections. | 07-28-2011 |
20110195916 | CYTOKINE PROTEIN FAMILY - The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides. | 08-11-2011 |
20110243888 | IL-29 MUTANTS AND USES THEREOF - The present invention relates to truncated IL-29 mutant molecules and methods of using same. The truncated IL-29 molecules can be used to treat viral infections, such as hepatitis C, autoimmune disorders and various types of cancer. | 10-06-2011 |
20110263484 | SINGLE CHAIN FC TYPE III INTERFERONS AND METHODS OF USING SAME - The present invention relates to single chain Fc Type III Interferon fusion proteins and methods of using same. The single chain Fc Type III Interferon fusion proteins comprise at least one Type III Interferon, two Fc regions and at least one linker, can be produced in a variety of single chain configurations, and are effector function minus or have a substantially reduced effector function. | 10-27-2011 |
20120004161 | HOMOGENOUS PREPARATIONS OF IL-28 AND IL-29 - Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity. | 01-05-2012 |
20120036590 | INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 02-09-2012 |
20120114590 | IL28 AND IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME - IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections. | 05-10-2012 |
20120142612 | CYTOKINE PROTEIN FAMILY - The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides. | 06-07-2012 |
20120251488 | USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS - Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics. | 10-04-2012 |
20120258458 | INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 10-11-2012 |
20130089517 | HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29 - Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity. | 04-11-2013 |
20130315911 | BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 11-28-2013 |
20140044676 | USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS - Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics. | 02-13-2014 |
20140178333 | HOMOGENOUS PREPARATIONS OF IL-28 AND IL-29 - Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity. | 06-26-2014 |
20150086552 | BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 03-26-2015 |